BENZODIAZEPINES, SERUM (See test detail)

Reference values, Method Modification

Test codes: 
745 - DIAZEPAM (VALIUM), SERUM
835 - LORAZEPAM, SERUM
1737-BROMAZEPAM, SERUM
2349-ALPRAZOLAM (TRANKIMAZIN), SERUM
5112-FLURAZEPAM, SERUM
1575-NITRAZEPAM, SERUM
983  -CLOBAZAN, NORCLOBAZAM AND RATIO, SERUM

Effective update from 10/06/2020

METHOD MODIFICATION FOR ALL THE TESTS. New methodology: Liquid Chromatography/Tandem Mass Spectrometry (LC-MS/MS)

TEST	Mnemonic	PREVIOUS	NEW
745	DIA	125-250 µg/L Toxicity: >3000 µg/L	Therapeutic level: 100 - 2500 µg/L Toxicity: Greater than 3000 µg/L Limit of quantification: 25 µg/L
835	LORA	Units: ng/mL Therapeutic level: 20 - 250 ng/mL Toxic levels are not defined	Units: µg/L Therapeutic level: 20 - 250 µg/L Toxicity: Greater than 300 µg/L Limit of quantification: 5 µg/L
1737	BRO	80-170 µg/L Toxicity: >300 µg/L	Therapeutic level: 50-200 µg/L Toxicity: Greater than 300 µg/L  (Greater than 2000 µg/L Letal) Limit of quantification: 10 µg/L
2349	ALPR	Units: ng/mL Therapeutic level: 11 - 20 ng/mL	Units: µg/L Therapeutic level: 5 - 50 µg/L Toxicity: Greater than 100 µg/L Limit of quantification: 2 µg/L
5112	FLURO	Units: ng/mL 10 - 110 ng/mL	Unidades: µg/L Therapeutic level: 20 - 100 µg/L Toxicity: Greater than 200 µg/L (Greater than 800 µg/L Letal) Limit of quantification: 3 µg/L
1575	NITRZ	Therapeutic levels: 30 - 100 µg/L Toxic levels: Greater than 200 µg/L	Therapeutic level: 30 - 100 µg/L Toxicity: Greater than 200 µg/L Limit of quantification: 20 µg/L
983	CLNC	Clobazam   :  30 -  300 µg/L Norclobazam: 300 - 3000 µg/L Norclobazam/Clobazam Ratio: Less than 10	Clobazam:    Therapeutic level: 30 - 300 µg/L    Toxicity: Greater than 500 µg/L    Limit of quantification: 10 µg/L Norclobazam:   Therapeutic level: 300 - 3000 µg/L   Limit of quantification: 50 µg/L   Ratio Norclobazam/Clobazam: Less than 10     NOTE:     Norclobazam / Clobazam ratio is useful for obtaining information on     drug metabolization capacity and improve dose adjustment.     Very high ratios (> 25) indicate that the patient is a slow metabolizer of the     CYP2C19 (if you are not taking CYP3A-inducing drugs or CYP2C19 inhibitors).     Note: The presence of Norclobazam should be assessed only in the case of therapy     without Clonazepam, since it interferes in the analysis.